SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

SNAP is trending amid chatter about potential AI integration and buyout speculation, with some drawing comparisons to Reddit's valuation.  The community is actively discussing potential short squeeze scenarios and identifying possible acquisition targets. Increased call option volume suggests a potential big move is on the horizon.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending due to investor excitement surrounding the potential return of founder Rabois and overall positive sentiment, with the community actively discussing a possible gamma squeeze and high price targets. A recent news article highlighting the stock's significant surge has further fueled the conversation. The stock is also garnering attention from people outside of the investment community.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors anticipate upcoming earnings, with community members debating potential outcomes and discussing the impact of factors like Pokemon card grading and collectible trading. Some traders are pointing to technical indicators and hedge fund loan balances, while others express frustration with the stock's sideways movement and await a catalyst for a breakout. Discussions also include Ryan Cohen's strategy and potential influence.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X, the first Bitcoin-native meme coin launched via the Runes protocol, is gaining traction for its fair distribution, strong community, and the utility it brings to Bitcoin miners. Community members believe $DOG.X has potential for substantial growth as the top meme coin on the Bitcoin blockchain. With a growing holder base and increasing visibility, many are comparing it to early Dogecoin and anticipating significant gains.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community discusses potential ETF approval and its impact on price, with some anticipating a rise to $1. Community members are also speculating about corporate treasuries potentially holding DOGE. Meanwhile, some traders are pointing to technical indicators suggesting a potential breakout.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is trending as natural gas prices fluctuate, sparking debates about potential bullish or bearish reversals. Community members are actively discussing weather forecasts, storage levels, and LNG exports as key factors influencing the commodity's price action. Some traders are eyeing potential short squeezes, while others remain cautious due to contango and overall market volatility.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Recent reports of updated data from the HARMONi Phase 3 trial, highlighting overall survival benefits in Western patients, are fueling discussion around Summit Therapeutics. While some investors express concern about the trial's primary endpoint and data analysis, others are optimistic, pointing to consistent global benefits and potential for FDA approval. The community is also speculating on potential partnership deals and comparing SMMT to competitor companies like IOVA.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to a recent land sale agreement, which is expected to significantly increase the company's NAV. The community is focused on the stock's low float and potential for a parabolic move, with some anticipating a short squeeze. Some traders believe GYRO is undervalued relative to its assets, while others point to risks associated with the company's liquidation plans.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

ProShares UltraShort Bloomberg Natural Gas ($KOLD) is trending as traders assess natural gas price movements amidst fluctuating weather forecasts and storage levels. Community members are closely monitoring technical charts, rig counts, and potential impacts of international energy deals. Discussions revolve around whether current conditions signal a buying opportunity or if bearish trends will persist.

United States Commodity Funds LLC - United States 12 Month Natural Gas Fund

United States 12 Month Natural Gas

UNL is trending as traders weigh bullish and bearish signals in natural gas futures, with community members actively discussing technical patterns like cup-and-handle formations and potential support/resistance levels. Bullish sentiment appears to be driven by the possibility of supply drawdowns and anticipation of seasonal strength, while bearish concerns stem from high production levels and storage. Some traders suggest UNL as a safer long-term play compared to leveraged options like $BOIL, due to its diversified futures holdings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor...

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Janux Therapeutics Announces Proposed Public Offering

<a href="https://stocktwits.com/symbol/JANX">Shares of Janux Therapeutics</a> Inc. surged over 54% on Tuesday afternoon, reaching levels not seen since May and breaking a five-day losing streak.&nbsp;The rally followed the company’s Monday announcement of promising Phase I trial data for its prostate cancer treatment, JANX007.In the trial, all 16 heavily pre-treated patients demonstrated a reduction of at least 50% in prostate-specific antigen (PSA) levels, a key indicator of cancer.&nbsp;The news sparked a wave of bullish analyst notes and retail investor enthusiasm.Stifel raised its price target to $115 from $70, citing increased probabilities of success for JANX007 in second- and third-line metastatic castration-resistant prostate cancer.&nbsp;The brokerage now forecasts $1.7 billion in risk-adjusted sales from these indications.&nbsp;Leerink boosted its price target to $91, highlighting the treatment’s “best-in-class” safety and efficacy profile.Cantor Fitzgerald took an even more optimistic stance, doubling its price target to $200. The brokerage praised JANX007 for achieving “unprecedented” PSA50 and PSA90 response rates while maintaining a tolerable safety profile.&nbsp;H.C. Wainwright also raised its target, albeit more modestly, to $70, increasing its probability of launch for JANX007 to 26% from 20%.<figure class="image"><a href="https://stocktwits.com/symbol/JANX"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/JANX_sentiment_and_message_volume_on_Dec_3_f914cb43e0.png" alt="JANX sentiment and message volume on Dec 3.png" width="1318" height="318"></a><figcaption>JANX sentiment and message volume on Dec 3 as of 2:15 pm ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned ‘extremely bullish’ amid a sharp increase in message volume, with many users seeing the breakthrough as a major milestone.&nbsp;The treatment, a tumor-activated T-cell engager, leverages the immune system by recruiting white blood cells to attack cancer cells.Janux has selected two once-weekly dose regimens for expansion trials targeting patients with two or three prior lines of therapy.&nbsp;The stock, up 460% year-to-date, is reportedly on track for its best year ever.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gm-stock-dips-after-plan-to-sell-battery-plant-stake/cJ9NCvaRhn">GM Stock Suffers Despite Battery Plant Stake Sale Plan: Retail Sentiment Dips To 5-Month Low</a>

Janux's stock, up 460% year-to-date, is reportedly on track for its best year ever.

Janux Therapeutics Stock Hits 7-Month High On Prostate Cancer Drug Trial Data: Retail Confidence Spikes

The treatment, a tumor-activated T-cell engager, leverages the immune system by recruiting white blood cells to attack cancer cells.

Equity

The treatment, a tumor-activated T-cell engager, leverages the immune system by recruiting white blood cells to attack cancer cells.


Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Navigating 5 Analyst Ratings For Janux Therapeutics

Latest Ratings for JANX
 DateFirmActionFromTo Jul 2021B of A SecuritiesInitiates Coverage OnBuy Jul 2021Cowen & Co.Initiates Coverage OnOutperform Jul 2021HC Wainwright & Co.Initiates Coverage OnBuy...

Analyst Expectations For Janux Therapeutics's Future

Janux Therapeutics Announces Updates to Board of Directors

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb PR Newswire VANCOUVER, BC, May 9, 2024 USA...

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.62	--	--	N/A
Q2 '25	-$0.46	-$0.55	-20.76%	MISSED
Q1 '25	-$0.37	-$0.38	-2.91%	MISSED
Q4 '24	-$0.46	-$0.36	21.85%	BEAT
Q3 '24	-$0.33	-$0.51	-55.81%	MISSED

JANX
Janux Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest JANX News

JANX Janux Therapeutics Inc